FDA Brief

Warning letters Biologics

FDA warning letter to

R3 Medical Companies

High riskIssued Aug 14Posted Aug 25Center for Biologics Evaluation and Research (CBER)

FDA cites R3 Medical affiliates for selling unapproved umbilical cord and exosome biologics without licenses and with serious manufacturing violations.

What happened

FDA inspected Bello Bio and Regen Suppliers, co-located in Scottsdale, Arizona, from November 17 to December 16, 2025, and issued Form FDA-483 inspection observations to each firm. FDA also reviewed the companies’ websites and social media, which promoted ReBellaWJ, ReBellaXO, ReBellaXOL and ReBellaCB for treating diseases and conditions such as arthritis, autism, diabetes and neurological conditions. FDA said the products are unapproved new drugs and unlicensed biological products and that manufacturing had current good manufacturing practice (CGMP) violations, including unvalidated aseptic processing and sterility testing that could miss contamination.

What FDA found

  1. The products are unapproved new drugs and unlicensed biological products because the company has no approved application or license to market them.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a); section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1)
  2. The products do not qualify for the cell and tissue exception because they are not intended for homologous use, meaning the same basic function in the recipient as in the donor, so they require premarket review as drugs or biologics.

    21 CFR 1271.10(a)(2) and 21 CFR 1271.10(a)(4)
  3. Aseptic manufacturing and cleaning/disinfecting of aseptic areas were not validated, even though the products claim to be sterile.

    21 CFR 211.113(b); 21 CFR 211.42(c)(10)(v)
  4. The manufacturing processes were not validated to assure identity, strength, quality and purity of the products.

    21 CFR 211.100(a)
  5. Sterility test samples were frozen and thawed before testing, which may hide contamination that was present.

    21 CFR 211.160(b)
  6. The company assigned a 24-month expiration date without stability data, and quality unit duties and procedures were not fully written or followed.

    21 CFR 211.166(a); 21 CFR 211.22(d)

What FDA wants

FDA tells the company to respond in writing within 15 working days with the specific steps it has taken or will take to correct the violations and prevent recurrence, plus supporting documentation. If it cannot meet that timeframe, it must explain the delay and give a completion date; if it disputes the findings, it must include its reasoning and support.

Who should pay attention

  • clinics and providers that buy or administer regenerative biologics
  • private-label distributors and brands of umbilical cord or exosome products
  • contract manufacturers of sterile cell and tissue products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk